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Innate Immunity and Its Regulation by Mast Cells
Ashley L. St. John*,† and Soman N. Abraham*,†,‡,x
Mast cells (MCs), which are granulated tissue-resident
cells of hematopoietic lineage, constitute a major sen-
sory arm of the innate immune system. In this review
we discuss the evidence supporting the dual role of
MCs, both as sentinels for invading pathogens and as
regulatory cells throughout the course of acute inflam-
mation, from its initiation to resolution. This versatility
is dependent on the ability of MCs to detect pathogens
and danger signals and release a unique panel of medi-
ators to promote pathogen-specific clearance mecha-
nisms, such as through cellular recruitment or vascular
permeability. It is increasingly understood that MCs
also contribute to the regulated contraction of immune
activation that occurs within tissues as inflammation
resolves. This overarching regulatory control over in-
nate immune processes has madeMCs successful targets
to purposefully enhance or, alternatively, suppress MC
responses in multiple therapeutic contexts. The Jour-
nal of Immunology, 2013, 190: 4458–4463.
Initiation of innate immune responses to pathogens
Immediate responses to pathogens are typically initiated in
epithelial tissues, such as the skin, intestinal/urogenital epi-
thelium, and nasal mucosa where environmental pathogens
are first encountered. Pathogens may also be injected into the
circulation by insect vectors or gain access owing to surgery or
medical interventions. Immunosurveillance for pathogens re-
lies on a wide array of pattern recognition receptors (PRRs),
which are hard-wired to recognize both extra- and intracellular
pathogens and pathogen-derived products (1, 2). Most cells
express PRRs, although nonimmune cells generally have fewer
types of PRRs or other mechanisms to limit unwarranted
activation. PRR-initiated signaling induces epithelial, endo-
thelial, or local immune cells, including dendritic cells (DCs),
monocytes, and macrophages (Mfs), to release cytokines and/
or antimicrobial agents (e.g., cathelicidin, b-defensins) (3,
4). Additionally, danger signals released from injured or dying
cells (e.g., ATP, heat shock proteins, bradykinins, and com-
plement split products) (5, 6) can potentiate signals received
through PRRs (7–11). Some responses prompt direct killing
of pathogens, such as complement activation, antimicrobial
peptides (AMPs), and phagocytosis/degradation by host cells
(3, 12). Both uninfected cells that detect pathogen-derived
products or infected cells may indirectly initiate the clear-
ance of pathogens through the recruitment of neutrophils, NK
cells, and others from the circulation. PRRs can also trigger
apoptosis or pyroptosis (13), resulting in the death of infected
cells, further facilitating infection clearance. These processes
are coordinated to resolve infection and, conversely, to avoid
immune pathology. There is growing evidence that mast cells
(MCs) are key regulatory cells capable of coordinating and
integrating many branches of the innate immune system.
Properties of MCs that allow innate immune regulation
MCs act as professional immune sentinels owing to several at-
tributes involving a heightened capacity to detect pathogens,
adaptations to promote communication within the tissue and
to distant sites, and their prime location as first responders to
pathogen colonization. As previously reviewed, the close as-
sociation of MCs with both epithelial and endothelial bar-
riers strategically places them among the first cells to encounter
pathogens (5, 14) along with other innate immune cells on the
front lines of infection, including DCs and Mfs. Initial de-
tection may not be due to direct pathogen exposure, as MCs
also sense danger signals emanating from the surrounding
tissue, including epithelial, endothelial, and tissue-resident
immune cells.
Depending on the balance of activating stimuli perceived by
MCs, they release a panel of inflammatory mediators with a
degree of specialization for the type of pathogen detected.
Stimuli such as many whole bacteria, parasite products, and
even the structure of certain viruses can induce release of an
MC’s cytoplasmic granules (15–17). At a site of infection in
vivo, host and pathogen-associated products likely have a
combinatorial effect to promote extensive degranulation. Re-
lease of vesicle-encased granules into the surrounding tissue as
vesicle-free particles usually begins within seconds of exposure
to degranulating stimuli. Granules are packed with inflam-
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matory mediators, including heparin, proteases, TNF, hista-
mine, and others. The dense granule structure promotes their
travel through lymphatics to draining lymph nodes (DLNs),
where they trigger the recruitment and sequestration of APCs
and T cells (18). However, extracellular granules contribute to
innate immunity, as well, by protecting inflammatory media-
tors from dilution or degradation and allowing the slow release
of associated products (19). In vivo, many particles also remain
trapped at the site of activation due to anatomical barriers (18).
DCs and Mfs can phagocytose extracellular MC granules
(20), which may be a mechanism of communicating to APCs
within the site of infection or DLN.
Delayed in comparison with degranulation responses, MCs
release de novo–produced inflammatory mediators (e.g., cyto-
kines, chemokines) requiring transcriptional changes with a
time course similar to other tissue-resident immune cells such
as DCs and Mfs. However, the MC-produced lipid media-
tors, eiocosanoids (i.e., leukotrienes and PGs), only require
enzymatic events to occur downstream of activating signaling
and, therefore, are also produced within minutes of activation
(21). As the first tissue-resident immune cells capable of re-
leasing prestored mediators in response to infection, MCs are
instrumental in determining the initial inflammatory media-
tor profile at a site of infection and, therefore, the quality and
character of the host response. The balance of signals in the
inflammatory milieu is ultimately highly influenced by the
initial information gathered by MCs through various recep-
tors for pathogens and their products.
PRR-dependent and -independent activation of MCs
MCs express multiple classes of PRRs: TLRs, Nod-like re-
ceptors (NLRs), Rig-I family receptors, and others (22–26)
(Fig. 1A). Few functional differences have been described
between rodent and human MCs, and yet there are differences
in TLR expression and cellular distribution. Human MCs ex-
press TLR1–TLR9 (22–24), although there have been varia-
tions in detection among many studies. TLR stimulation
generally produces signaling below the threshold required to
generate calcium flux and granule exocytosis, except, poten-
tially, peptidoglycan stimulation through TLR2 (27). TLR-
induced signaling in MCs, similar to other cells, results in
stimulus-specific transcriptional activation and production
of cytokines/chemokines (5) and also attunes other MC re-
sponses. For example, pretreatment of MCs with TLR ago-
nists results in sensitization and enhanced degranulation in
response to IgE cross-linking through Fc«R1 (28). Eiocosinoid
pathways are also activated by TLR signaling (29). In some
contexts, MCs may be one of the only cells proximal to an
infection site capable of detecting certain pathogen-asso-
ciated motifs. For example, in the lung, MCs express TLR10
and TLR7, which are not abundantly expressed or induced with
TLR stimulation by lung epithelial cells (30, 31). The role of
TLR10 on MCs has not been described; however, TLR7 ago-
nists induce MC-dependent localized tissue inflammation and
adjuvant activity, implying that a similar response may occur
to ssRNA during infection (32, 33). Illustrating the potency of
TLR7 activation on MCs, the TLR7 agonist imiquimod was
recently shown to promote CCL2 production by MCs and, in
turn, the recruitment of plasmacytoid DCs that directly killed
tumor cells. This response was independent of the adaptive
immune system and provides a MC-dependent mechanism of
the effectiveness of imiquimod against skin cancers (34).
The best characterized PRR responses of MCs are those
directed toward bacterial products: LPS through TLR4, fla-
FIGURE 1. Pathogen recognition
and innate immune regulation by
MCs. (A) MCs respond to diverse
subtypes of pathogens and pathogen-
associated motifs due to their expres-
sion of PRRs and additional unique
cellular receptors. Receptors that are
used by MCs, the cellular location of
the receptor (cell surface versus
endosomal versus cytosolic), and the
class of pathogen or pathogen-associ-
ated molecular pattern (PAMP) that
the receptor recognizes are summa-
rized. (B) Unique events are promoted
by MCs in response to different path-
ogens and based on tissue-specific MC
capabilities. The release of MC prod-
ucts can promote cellular recruitment,
vascular leakage, and other physical
processes that are central to combating
pathogens, such as mucus production.
Additionally, MCs play a regulatory
role in the tissue remodeling and im-
mune contraction processes that must
occur subsequent to inflammation to
restore homeostasis.
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gellin through TLR5 (on human MCs), and peptidoglycan
through TLR2 (5). MCs also express TLRs for detection of
viral products (e.g., TLR3, TLR7, and TLR9). Indeed, TLR3
stimulation by polyribosinic-polyribocytidylic acid results in
activation of MCs (24). Both Newcastle virus and dengue
virus have been shown to activate MCs to produce cytokines
and chemokines, including CCL5, CXCL12, and CX3CL1
(15, 35). For dengue, this response occurred through syner-
gistic activation of the TLR3 and RIG-I pathways, resulting
in production of type I IFNs and chemokines (15). However,
the signaling pathways that are activated by TLR stimulation
may not always benefit the host. In HIV-infected MCs, TLR
stimulation augmented viral replication (36). Although the
mechanism is not understood, this illustrates that highly host-
adapted pathogens can also exploit immune activation by
MCs. NLRs recognize cytoplasmic microbial products and
have primarily been studied in the context of mucosal MCs
(25). NLR activation initiates inflammasomes, intracellular
multiprotein oligomers that promote inflammation, caspase
cascade activation, and cleavage to the active forms and se-
cretion of cytokines, including IL-1b and IL-18 (37). In-
flammasomes are not only implicated in pathogen defense,
they have also been associated with some kinds of sterile in-
flammation. An interesting MC-related example is cryopyrin-
associated periodic syndrome, a rare inflammatory disorder
linked to certain NLRP3 mutations where individuals have
chronic uticaria, a common symptom of MC activation. MCs
with NLRP3 mutations have constitutive activation of inflam-
masomes leading to chronic production of IL-1b, heightened
recruitment of neutrophils, and increased vascular leakage in
mouse models, in the absence of degranulation (38). Thus,
defects in the pathogen recognition signaling circuitry in this
powerful immunomodulatory cell can result in inflammatory
dysregulation with severe consequences.
Beyond traditional PRRs, MCs use other molecules that
directly detect pathogens or their products (5). These trigger
a variety of responses, some of which are anomalous or sub-
optimal and may favor pathogen survival. For example, CD48
serves as a receptor for fimbriated Escherichia coli and several
other bacterial pathogens (5, 39). CD48 not only induces MC
degranulation, but also bacterial uptake without intracellular
degradation, creating intracellular bacterial reservoirs (40).
MCs express receptors for bacterial-secreted toxins, including
Clostridium difficile toxin A, Bordetella pertussis toxin, and
cholera toxin. Whereas C. difficile toxin A triggers MCs to
provoke hypersecretion in the gut, B. pertussis toxin inhibits
MC secretion of most of its cytokines, and cholera toxin
elicits MC secretion of a few cytokines but not degranulation
(41–43). Thus, pathogen virulence factors also can activate
non-PRRs to elicit potentially counteractive responses. The
nature and magnitude of MC responses to a given pathogen
are likely to be dictated by the cumulative outcome of op-
posing signals among many pathogen-sensing receptors.
MC modulation of innate responses to pathogens
Genetically modified mouse models are used to address the
functional consequences of MCs in vivo, although each has
inherent caveats (recently reviewed in Ref. 44). To date, most
of these studies have been performed in mice lacking MCs
owing to mutations in the promoter region of the c-kit gene
(“sash” mice) and have supported that MCs amplify immu-
nity and enhance the kinetics of an inflammatory response
(44). Even without MCs, many immune cells can recognize
pathogens in peripheral tissues; however, in certain contexts,
the advantage the host receives through the actions of MCs can
influence survival during infection (5). MC responses to bac-
teria are better understood, but limited studies using viruses or
parasites have emphasized that MCs modulate the nature and
magnitude of innate responses uniquely, depending on the
infecting pathogen and infection site. MCs produce a powerful
type I IFN response to viruses but not when challenged by
bacteria, presumably because IFN-b negatively impacts neu-
trophil recruitment, a key mode of bacterial clearance (45).
At mucosal sites, MC granules have dominant incorpora-
tion of the protease tryptase, less histamine, and use the proteo-
glycan chondroitin sulfate as a scaffold for their mediators, in
contrast to connective tissue type MCs, which include tryptase
and substantial amounts of chymase on a scaffold of heparin
(46). The subsets of human MCs are less well characterized
than rodent MCs and do not appear distinguishable as mucosal
or connective tissue subtypes as readily, but they also display
heterogeneity (46). These differences likely reflect the need for
unique strategies to counteract pathogens that colonize differ-
ent sites (Fig. 1B). Although many immune cell types and
factors contribute to parasite clearance from mucosal sites (47),
mucus production, which facilitates the physical flushing of
pathogens (e.g., Trichella spiralis) from mucosal surfaces,
is a key aspect of MC-promoted innate immunity (5). During
Nippostrongylus brasillienis infections of the gut, parasite ex-
pulsion is linked to increased mucus secretion by goblet cells,
which are regulated by MC products such as histamine (48).
Histamine-mediated secretion by goblet cells has also been
observed in the lungs (49). Although the benefit is not im-
mediately clear, products of mucosal MCs, particularly LTC4
(another secretagog for goblet cells), induce bronchocon-
striction during viral infections by triggering smooth muscle
contraction (50, 51). MCs also bridge communication be-
tween the immune and nervous systems (Fig. 1B) by pro-
ducing neurotransmitters and other mediators, such as nerve
growth factor, serotonin, substance P, and NO (52). In ad-
dition to inflammatory pain, MC-to-neuron communication
likely contributes to processes, such as gut motility, that pro-
mote parasite expulsion (53, 54).
Mediators that regulate vascular flow and permeability
(e.g., histamine, proteases, leukotrienes) dominate early MC
responses (14) (Fig. 1B). These mediators also facilitate the
cellular recruitment from the circulation and into infection
sites, in part, due to the upregulation of adhesion molecules on
vascular endothelium. MC-derived TNF recruits neutrophils
to sites of bacterial infection (55) and induces expression of
E-selectin on blood vessels during cutaneous E. coli infection,
which allows accumulation of multiple DC subsets within
tissues (56). In contrast to the dominant recruitment of neu-
trophils during bacterial infection, MCs recruit unique cell
types in response to other classes of pathogens (Fig. 1B), in-
cluding eosinophils to sites of parasite infection and cytotoxic
cells during viral infection (15, 57). MC products also promote
the recruitment of basophils (58). CD8+ T cells and IFN-
producing plasmacytoid DCs are recruited in response to
TLR3 and TLR7 stimulation of MCs in vivo, respectively (34,
35). MCs also promote the accumulation of NK and NKT
cells to the skin and DLNs during viral infection, thus
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enhancing viral clearance (15). In each of these examples, MCs
promote chemotaxis of innate immune cells, at least in part
through the production of chemokines. MC interaction with
NK cells during inflammation may extend beyond their re-
cruitment. For example, LPS or CpG-activated MCs physi-
cally interact with NK cells to promote enhanced IFN pro-
duction that is contact- and TNF-dependent (59), suggesting
that the physical interactions between MCs and NK cells that
have been observed during viral infection within tissues (15)
may be sites where this type of communication occurs.
MCs need not only rely on recruited cells to clear patho-
gens, but they also produce compounds that have direct
killing activity (60). AMPs are short-charged peptides that
are thought to generate pores in microbial but not eukaryotic
membranes. One AMP, cathelicidin, has direct killing activity
against certain bacterial and viral pathogens. It is granule-
associated and is also inducible in MCs (16, 60). Granule
proteases, many of which are MC-specific, may also act in
tissues to break down microbial virulence factors or toxins,
similar to snake venom toxins, which can be neutralized by
MC granules (61).
Inhibitory functions of MCs
MCs initiate proinflammatory cytokine production, but they
also inhibit these responses when a situation warrants such
action. This may serve multiple purposes: to restore homeo-
stasis after pathogen clearance, prevent tissue damage due to
prolonged inflammation, or to facilitate wound repair. Recent
studies emphasize the role of MCs in maintaining peripheral
tolerance or preventing excessive inflammation (62–64).
During bladder infection, the initial proinflammatory re-
sponse of MCs to E. coli is followed by production of tradi-
tionally immunosuppressive cytokines, including IL-10, pro-
moting tolerance in the bladder (64). Because IL-10 also
promotes certain aspects of tissue regeneration (65), it might
facilitate postinfection healing. MCs are thought to reduce
scarring during wound healing, as does IL-10 (65, 66).
Whereas recent studies have suggested that IL-10 does not
promote wound closure, and perhaps even delays the process
(67), IL-10 is a mitogenic factor for MC progenitors (68).
MCs also produce TGF-b, which suppresses the function of
Mfs and DCs in vivo (64, 69). For Mfs, TGF-b reduces the
TLR-activated transcription of cytokines such as TNF and
CCL3 and reduces NO production by preventing expression
of iNOS (70), likely another mechanism by which MC-
derived TGF-b acts in a tissue as an infection clears. These
studies illustrate that the sentinel function of MCs is followed
by a key role in the regulated resolution of inflammation.
MC-directed responses may also promote immunity in one
context while having a suppressive function in another. In one
study, it was observed that MC interactions with monocytic
myeloid-derived suppressor cells suppressed antitumor im-
munity whereas MC interactions with granulocytic myeloid-
derived suppressor cells enhanced clearance of parasites (71).
Thus, MCs may have widely divergent proinflammatory or
immunosuppressive effects depending on the cell types that
they recruit to, or encounter within, an inflammatory milieu.
MC responses in excess
MC-mediated innate immunity usually promotes timely res-
olution of acute infection, but the role of MCs is markedly
more complex in chronic infections. During lung mycobac-
terial infections, MC regulation of the local cytokine milieu
encourages the development of granulomas, which, paradox-
ically, both contain bacterial spread and protect bacteria from
total clearance (72). MCs may also promote chronic infec-
tions and exacerbate associated pathologies depending on the
pathogen species and load, the site of infection, or any pre-
existing inflammatory disease. Examples include staphylococcal
infections in atopic dermatitis, Pseudomonas aeruginosa infec-
tions of inflamed cystic fibrotic lungs, and Helicobacter pylori
infections in chronic gastritis (73–75). MCs exacerbate in-
flammation through hypersecretion of mediators such as
IL-1a and IL-1b (74) or by anomalous recruitment of cyto-
toxic cells, for example, neutrophils and eosinophils. Recently,
MC-derived IL-1b and TNF were reported to contribute to
indigenous microbiota-induced skin disease in neonatal mice,
and a mechanism involving aberrant NLRP3 inflammasome
signaling was implicated, with MC hyperplasia further am-
plifying pathology (75). MCs can actively proliferate at sites
of chronic inflammation, such as in the gut mucosae during
parasite infection (17). It is assumed that immature or newly
recruited MCs constitute the proliferative subset in tissues,
but further studies are needed to address which subsets of
MCs can proliferate in tissues and how their maturation and
activation levels influence cell cycle regulation. MCs also can
undergo multiple cycles of prestored or de novo–synthesized
mediator release (5). Between cycles of degranulation there
may be a refractory period due to depletion of intracellular
granule stores or desensitization to repeated Ag challenges
(76). Harmful effects of MCs are more likely when the
pathogen load is high and widespread, such as during bacterial
sepsis. The location of MCs near the vasculature where their
mediators can rapidly gain access into blood vessels probably
contributes to pathology (14). A functional comparison of
systemic versus regional MC responses during bacterial in-
fection has emphasized that MCs mediate both beneficial and
harmful host responses (77). Although prompt and localized
MC activation during infection usually is beneficial, systemic
and sustained MC activation, typically associated with chronic
or severe systemic infections, may not be.
Purposeful activation or tempering of MCs
The immunoregulatory capacity of MCs may also be rele-
vant to vaccine design and immunization. For example,
mucosally or s.c. delivered MC activators can enhance im-
munity to vaccine Ags (78). MC activators promote recruit-
ment of cells, including APCs, to vaccination sites without
signs of toxicity (78). Enhanced Ag-specific immunity was
induced when vaccines were coadministered with synthetic
MC granules, being nanoparticles comprised of a carbohy-
drate scaffold loaded with cytokines (19). Thus, by activating
MCs or directly applying MC products during vaccination,
it is possible to markedly boost immune responses to the
accompanying Ag. It is conceivable that MC activators or
simulators of MC granules could also be used therapeutically
against infection. Therapeutic modulation of MCs has been
explored in the context of suppressing unwanted inflamma-
tion, and TLR7 on MCs is a promising target. MCs are
central to the mechanism of action of the TLR7-modulating
drug imiquimod, and therapeutic administration of a weakly
agonistic TLR7 ligand was shown to reduce MC-driven
The Journal of Immunology 4461
neutrophil influx during chemically induced colitis (34, 79).
Another TLR7 agonist reduces allergic responses associated with
rhinitis in humans, assumed to work by promoting a shift in
the inflammatory profile of nasal MCs from Th2 to Th1 (80).
In chronic infections or those that exacerbate pre-existing
inflammatory conditions where MCs contribute to the asso-
ciated pathology, MC stabilizers may be of benefit. For ex-
ample, treatment of T. spiralis–infected rodents with the MC
stabilizer ketotifen reduced MC hyperplasia and hypermotility
of the gut, a motor disturbance similar to that observed in ir-
ritable bowel syndrome (81). MC stabilizers and antihistamines
are used to treat asthma, including episodes precipitated by
viral infections (82).
Conclusions
MCs evolutionarily predate most cells of the immune system,
including the adaptive immune system (83). Consequently,
they possess broad and overarching functions that integrate at
many levels with immune processes that arose later during
vertebrate evolution. Utilizing the canonical innate immune
pathways, they discriminate between self and non-self. When
a pathogen-specific motif has been detected, they alert the host
of an infection while directly mediating pathogen clearance.
MCs possess a broad repertoire of receptors to detect infec-
tions: traditional PRRs, other receptors that directly sense
pathogens, and receptors for endogenous danger signals re-
leased by infected and injured host cells. To some individual
stimuli and nearly always in the context of true infection where
multiple pathways are activated simultaneously, MCs release
discrete nanoparticles within minutes that are loaded with
proinflammatory mediators. By virtue of being tissue-resident
and presynthesizing and storing mediators, MCs enhance the
kinetics of the inflammatory response and can amplify the
activation levels of neighboring immune cells. They can release
a substantial amount of mediators whereas other innate im-
mune cells are still only beginning to modify their transcrip-
tional programs. The particulate form of an exocytosed granule
prolongs the longevity of its cargo and also facilitates its
transport to distal sites or uptake by phagocytic cell types that
participate in the innate immune response (19). Degranulation
is followed by regulated secretion of a pathogen-specialized
panel of de novo–synthesized mediators. The preponderance
of MCs at mucosal sites, in skin and near blood vessels, makes
them uniquely capable of sensing early infection and coloni-
zation events. Their close physical association with blood
vessels promotes leukocyte recruitment to infection sites and
systemic dispersal of MC products. MCs also regulate the
quality and magnitude of their responses depending on the
pathogen, the stage of infection, and their location. These
observations reveal temporally and spatially specific aspects to
MC responses. Although the actions of MCs early in infection
are thought to be mostly beneficial, they can have a detri-
mental impact during chronic or overwhelming infection. In
these cases, and in certain disorders involving aberrant innate
activation during sterile inflammation, the sensory and se-
cretory properties of MCs become counterproductive or
pathological. With the growing recognition of the critical
role played in MCs in promoting beneficial innate responses
during infections as well as in exacerbating infection and pro-
moting pathologies, it may be possible to judiciously employ
MC-modulating compounds for therapeutic effect.
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